Digipath
Home > Boards > US OTC > Medical - Drugs >

OncBioMune Pharmaceuticals Inc. (OBMP)

OBMP RSS Feed
Add OBMP Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, Weedman1
Search This Board: 
Last Post: 1/19/2019 3:02:20 AM - Followers: 108 - Board type: Free - Posts Today: 1

Image result for biotech

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane).  


 





Press releases: http://oncbiomune.com/news/

SEC Filings: https://www.sec.gov/cgi-bin/browse-edgar?company=oncbiomune&owner=exclude&action=getcompany

Quote: https://www.otcmarkets.com/stock/OBMP/overview

Clinical trials: 
 https://clinicaltrials.gov/ct2/results?cond=&term=oncbiomune&cntry=&state=&city=&dist=





CHIEF LEADERSHIP

 

Image result for Dr. Jonathan Head

Dr. Jonathan Head, Ph.D.

  

CHIEF EXECUTIVE OFFICER, CHAIRMAN

Dr. Head has been instrumental in the development of our new chemotherapy and immunotherapy programs. Dr. Head and Dr. Elliott are the co-developers and patent holders of one of the first patented autologous breast cancer vaccines in the United States.  His major goal is to implement translational research – the movement of laboratory-developed technologies into the clinical setting.  This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.

As a tumor cell biologist, Dr. Head’s specialties include:

Cell culture research
Animal research
Human clinical research
Innovative chemotherapies
Immunotherapy/cancer vaccines
Oncogene and antisense research
Tumor markers

Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine.   He is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Although patients rarely meet Dr. Head, the new treatments we offer are the result of his and Dr. Elliott’s work.

 
 



Image result for Dr. Robert Elliott


Dr. Robert Elliott, M.D., Ph.D.

 
 

CHIEF MEDICAL OFFICER

Dr. Robert Elliott is the driving force behind our The Elliott-Elliott-Head Breast Cancer Research and Treatment Center.  Colleagues often remark that his energy seems boundless. Indeed, it often is.

In 1973, when the Center was founded, Dr. Elliott’s dream was to create the finest center for total breast care. With that step behind us, the dream continues.  Dr. Elliott continues doing research to discover new treatments and drug therapies, and has implemented a team approach to bring total breast care to the patients.

Dr. Elliott sees patients from all over Louisiana, the Southeast and across the United States. He collaborates on research projects with other scientists around the world. Dr. Elliott has spoken to medical audiences in the United States and Europe and has authored many papers and abstracts. He has also published a book, Breast Cancer, Anger at the Enemy, which deals with the lack of total breast care available for women. He shares his own frustration and heartaches of caring for dying cancer patients as they struggle for survival, and finally sends a message of hope as he and his research team search for a cure for breast cancer.

Trained as a general surgeon, Dr. Elliott feels that breast care should be a specialty of itself, with patients being able to receive the highest quality of care from one physician who reads their mammograms, examines them, performs their surgery and administers their therapies.

To advance this concept and to share his experience with other physicians like himself who specialize in breast care, Dr. Elliott founded the American Mastology Association. He currently serves as President of this society. In spite of a busy calendar of meetings and research, Dr. Elliott’s first love is his patients. He devotes the majority of his time to the Center and to helping women overcome breast disease.


 
Andrew Kucharchuk
 

CHIEF FINANCIAL OFFICER, PRESIDENT, DIRECTOR

Andrew “Al” Kucharchuk is a graduate of Louisiana State and Tulane Universities Freeman School of Business, where he earned an MBA with a Finance Concentration. He currently serves as the Company’s Chief Financial Officer and oversees the business and administrative processes.  In addition to these duties, Al also directs business development efforts including the expansion of operations to accommodate increased research and clinical development. Al has assisted Dr. Head in the administration of the three contracts that have lead to the clinical studies for the Company’s lead product, ProscaVax™.

Mr. Kucharchuk is a member of Kappa Alpha Order fraternity. He lives in Baton Rouge with his wife Jessica and their sons Henry and Davis.

 
 

Charles L. Rice, Jr.

 
DIRECTOR

Mr. Rice is the President and Chief Executive Officer of Entergy New Orleans, Inc., an $800 million a year electric and gas utility and subsidiary of NYSE-listed Entergy Corporation.  After his first legal private practice position in Louisiana with Jones, Walker, Waechter, Poitevent, Carrere & Denegre, L.L.P, Rice joined Entergy in the legal department in 2000, serving as senior counsel in the Entergy Services, Inc. litigation group and then as manager of labor relations litigation support in human resources.

Rice was recruited into New Orleans city government in 2002 as the city attorney and later took the critical role of chief administrative officer for the City of New Orleans, where he managed 6,000 employees and the city’s $600 million budget. In 2005, the law firm of Barrasso, Usdin, Kupperman, Freeman & Sarver, L.L.C. recruited him back to private practice, where he was named partner.

Returning to Entergy in 2009, Rice served as director of utility strategy where he was responsible for coordinating regulatory, legislative, and communications efforts to develop and execute strategies that advanced commercial objectives for the company’s regulated service areas. He then served as director of regulatory affairs for Entergy New Orleans.

Rice holds a bachelor’s degree in business administration from Howard University, a juris doctorate from Loyola University’s School of Law and master’s degree in business administration from Tulane University. After graduating from Howard University, he was commissioned as a second lieutenant in the United States Army and served as a military intelligence officer with the 101st Airborne Division (Air Assault) at Fort Campbell, KY. While in the Army, he earned the Airborne Badge, Air Assault badge and was awarded the Army Commendation and the Army Achievement medals.

He is a member of the Alabama and Louisiana State Bar Associations, the American Bar Association, the New Orleans Bar Association, and the National Bar Association.

 
 

Daniel Hoverman


DIRECTOR

Daniel Hoverman is a Director at NYSE-listed Houlihan Lokey, a leading global investment bank, where he is a senior member of the firm’s Corporate Finance Group. Mr. Hoverman is also actively involved with Houlihan Lokey’s efforts in equity capital markets.

Mr. Hoverman has extensive mergers and acquisitions advisory and financing experience, having completed over $100 billion of transactions for both private and public companies across multiple industries and geographies. Before joining Houlihan Lokey, he was a Director with Credit Suisse in Hong Kong as a member of the office of the General Counsel, and was responsible for oversight and management of investment banking transactions. Prior to Credit Suisse, he was a Director with UBS Investment Bank in New York as a member of the firm’s Equity Capital Markets Group and Equity Corporate Finance Team, where he was responsible for origination, oversight and management of securities offerings. He began his career with Kirkland & Ellis LLP as a corporate attorney focusing on capital markets and mergers and acquisition transactions.

Mr. Hoverman received a B.A. from Yale University, where he graduated cum laude with distinction in history and was a Robert C. Bates Fellow and New Prize recipient, and received a J.D. and M.B.A. from Columbia University, where he was a James Kent Scholar and a John C. Olin Fellow. Mr. Hoverman holds Series 7, 24, 63 and 79 licenses and the designation of Chartered Financial Analyst, and is an inactive member of the New York Bar.




Dr. J. Jacques Carter

 

SCIENTIFIC ADVISORY BOARD MEMBER

Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

Dr. Carter completed his residency training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, followed by a graduate program at the Harvard School of Public Health, where he received his MPH degree. He then completed a clinical fellowship in Primary Care Medicine at the Massachusetts General Hospital.

Dr. Carter has held a number of clinical and administrative positions, including Medical Directorships of several local and national health care organizations. A former director of one of the major clerkships, he now serves as a teacher/advisor/mentor for students at Harvard Medical School and the Harvard School of Public Health. Dr. Carter has been active in a number of civic and community organizations, including past president of the board of Family Service of Greater Boston and past chair of the Brookline Advisory Council on Public Health. He regularly gives talks on medical and health related issues to community groups and students throughout greater Boston. He also lectures nationally and internationally on medical and public health topics. Dr. Carter serves as a medical consultant and resource for members of the media. He is a past President of the Harvard School of Public Health Alumni Association and a current director of the Harvard Alumni Association. Dr. Carter is a founding member of the Georgetown University African American Advisory Board. He is the recipient of the 2010 Harvard Medical School/Harvard School of Dental Medicine Community Service Lifetime Achievement Award. His bio has been included in “Who’s Who in the East, “Who’s Who in Medicine and Healthcare”, Who’s Who in Science and Engineering, and “Who’s Who in America”.



OBMP pipeline
 

http://oncbiomune.com/pipeline/
 

¹Upon completion of a successful Phase 1 study, the Company plans to begin a Phase 2 study at Harvard Cancer Centers.

 

Phase 2 clinical trial of ProscaVax for early-stage prostate cancer to be hosted at Beth Israel Deaconess Medical Center a teaching hospital of Harvard University Medical School in Boston, MA.

ProscaVax is OncBioMune’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Per the study protocol, patients to be enrolled will be in what is termed “active surveillance,” a disease management option for patients with localized prostate cancer that elect to work with their doctor to monitor the disease for progression before taking more drastic intervention measures, such as surgery or radiotherapy.  To the Company’s knowledge, the trial of ProscaVax is the first ever worldwide for a prostate cancer vaccine technology addressing the active surveillance patient population.

http://oncbiomune.com/2018/06/20/oncbiomune-to-commence-phase-2-trial-of-proscavax-for-early-stage-prostate-cancer-patients/


Concurrent with the Phase 2 trial of patients in active surveillance, the Company is undergoing the approval process to initiate a Phase 2 trial of ProscaVax in hormone-naïve recurrent prostate cancer patients with increasing PSA at the Urology Clinics of North Texas.

 
 
 

OBMP Daily Chart





 

OBMP Weekly Chart



 

OBMP SECURITY DETAILS

Share Structure

 
Authorized Shares
500,000,000
Outstanding Shares
223,744,842
Restricted
117,530,685
Unrestricted
89,207,059
Held at DTC
89,059,869
Float
9,773,505
https://www.otcmarkets.com/stock/OBMP/security

Last 10-Q

https://www.sec.gov/Archives/edgar/data/1362703/000149315218008916/form10-q.htm
 
 
Contact:
http://oncbiomune.com/
OncBioMune Pharmaceuticals, Inc.
Jonathan Head, Phd
Chief Executive officer and Chairman
Jhead@oncbiomune.com                 Image result for biotech


 

 

Digipath
OBMP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OBMP News: Current Report Filing (8-k) 12/27/2018 03:13:35 PM
OBMP News: Quarterly Report (10-q) 11/14/2018 03:56:00 PM
OBMP News: Small Company Offering and Sale of Securities Without Registration (d) 10/09/2018 04:16:50 PM
OBMP News: Current Report Filing (8-k) 09/26/2018 05:06:50 PM
OBMP News: Quarterly Report (10-q) 08/14/2018 04:37:13 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#7360  Sticky Note Probably the best written PR I've read from BooDog 11/08/18 11:08:53 AM
#7279  Sticky Note Welcome To All New Potential Investors: BooDog 11/01/18 09:16:38 AM
#7958   I think you may be correct something is jcbaby 01/19/19 03:02:19 AM
#7957   Shh, Be Vwery, Vwery Quiet I'm getting ready CanItBThisEZ2Make 01/18/19 11:22:43 PM
#7956   Impatience or the need for immediate funds perhaps. Weedman1 01/18/19 03:11:33 PM
#7955   I don't disagree with you. There certainly southerngent1 01/18/19 02:37:18 PM
#7953   * sniff sniff * You guys smell that? Weedman1 01/18/19 01:56:09 PM
#7952   Is it just me or is everybody noticing Weedman1 01/18/19 01:08:20 PM
#7951   No gossip. Only observation. U made it easy StoneStreetProsper 01/17/19 09:11:08 PM
#7950   While you're all busy gossiping about me the learningcurve2020 01/17/19 04:15:56 PM
#7949   He’s so predictable. It’s entertaining StoneStreetProsper 01/17/19 10:13:15 AM
#7947   Prior toxic funder. why listen to him? southerngent1 01/16/19 10:53:42 PM
#7946   Im buyimg more shares this week ! southerngent1 01/16/19 10:52:29 PM
#7945   Nothing insider about it. Also, I knew you’d StoneStreetProsper 01/16/19 09:43:49 PM
#7944   So much insider here-say. LOL Where's learningcurve2020 01/16/19 09:25:16 PM
#7943   Can't say I didn't tell you. learningcurve2020 01/16/19 09:17:35 PM
#7942   I’m not expecting this baby to move until StoneStreetProsper 01/16/19 04:09:07 PM
#7941   The reasons for the delay are good and StoneStreetProsper 01/16/19 04:07:45 PM
#7940   We can always look to you for words southerngent1 01/16/19 02:32:41 PM
#7939   Years of wasted time. learningcurve2020 01/16/19 02:18:02 PM
#7938   "PICK ME! PICK ME!!" $OBMP cries loudly. BooDog 01/16/19 07:16:36 AM
#7937   Way to go Leadership! >>WASHINGTON—U.S. startups received learningcurve2020 01/15/19 11:47:48 PM
#7936   If it did I am going to buy southerngent1 01/14/19 03:02:10 PM
#7935   Oh well. learningcurve2020 01/14/19 01:31:34 PM
#7934   Went below a penny? learningcurve2020 01/14/19 01:30:37 PM
#7933   Danny, You said it was little to begin with. southerngent1 01/14/19 12:29:59 PM
#7932   Can you do anything with what little is learningcurve2020 01/14/19 10:38:51 AM
#7931   I work in the industry (financial planning) and Tanker12 01/11/19 02:19:59 PM
#7930   I for one would absolutely love to see Weedman1 01/11/19 02:14:23 PM
#7929   Volume is really up today. Maybe we will Tanker12 01/11/19 02:10:55 PM
#7928   I can't find the article right now but Brokerman101 01/11/19 12:23:32 PM
#7927   You should be concerned about FDA approval since learningcurve2020 01/11/19 11:52:56 AM
#7926   While this company is highly speculative to say Brokerman101 01/11/19 10:34:34 AM
#7925   Yes almost all bio penny stocks are hilarious! learningcurve2020 01/11/19 08:55:02 AM
#7924   I guess you're going to have to wait learningcurve2020 01/11/19 08:51:18 AM
#7923   I believe the great philosopher Justin Timberlake said Crawfors 01/10/19 09:15:49 PM
#7922   Hudsondogg approves your message HudsonDogg 01/10/19 06:19:20 PM
#7921   you may hate it but it ain't no Crawfors 01/10/19 01:01:45 PM
#7919   Hey whatever works. Seems to feel much more Weedman1 01/09/19 05:00:09 PM
#7918   What excuses are you talking about ???? southerngent1 01/09/19 04:15:07 PM
#7917   Dopey, Its Hilarious how your posts for NWBO HudsonDogg 01/09/19 03:56:21 PM
#7916   Stop with the endless excuses already! No I don't learningcurve2020 01/09/19 03:40:38 PM
#7915   Maybe to delay the cc they hired a learningcurve2020 01/09/19 03:34:29 PM
#7914   The next PR should be on the exact southerngent1 01/09/19 12:24:53 PM
#7913   Hiring of new CEO is why the CC Weedman1 01/09/19 12:01:16 PM
#7912   Market cap isn't going to grow until studies HudsonDogg 01/09/19 11:59:48 AM
#7911   Said it before, if this IP is at learningcurve2020 01/09/19 11:19:37 AM
#7910   Jeez. I didn't say he wasn't I HudsonDogg 01/09/19 10:29:35 AM
#7909   “As an oncologist and as I’ve gotten to StoneStreetProsper 01/09/19 10:22:20 AM
#7908   So you would rather him say that he HudsonDogg 01/09/19 09:53:56 AM
#7907   LOL. Well then there's not much reason learningcurve2020 01/09/19 09:48:42 AM
#7906   Hey, look at that! “I am excited learningcurve2020 01/09/19 09:38:37 AM
PostSubject